Better outcomes have been demonstrated with coronary artery bypass grafting (CABG) than with percutaneous coronary intervention (PCI) in three-vessel coronary artery disease (CAD). However, the PCIs performed in these studies were guided by angiography, not fractional flow reserve (FFR) measurements. … Continue Reading about FAME 3 noninferiority trial: FFR-guided PCI vs CABG
Main Content
Latest Videos
Frontiers in Cardiology
FAME 3 noninferiority trial: FFR-guided PCI vs CABG
Better outcomes have been demonstrated with coronary artery bypass grafting (CABG) than with percutaneous coronary intervention (PCI) in … Continue Reading about FAME 3 noninferiority trial: FFR-guided PCI vs CABG
COAPT Trial: Renal dysfunction and cardiac outcomes in heart failure
Patients with heart failure (HF) and severe secondary mitral regurgitation (MR) frequently also suffer from baseline renal disease (RD). … Continue Reading about COAPT Trial: Renal dysfunction and cardiac outcomes in heart failure
Current trends
Greater risk of death in heart failure patients hospitalized for COVID-19
The CAPACITY-COVID Collaborative Consortium and LEOSS Study Group examined outcomes of hospitalized COVID-19 patients, both with and without pre-existing heart disease. The CAPACITY-COVID (NCT04325412) … Continue Reading about Greater risk of death in heart failure patients hospitalized for COVID-19
Empagliflozin and Renal Outcomes in Heart Failure
The EMPEROR-Reduced (NCT03057977) and EMPEROR-Preserved (NCT03057951) trials demonstrated that empagliflozin could reduce the risk of hospitalization for heart failure (HF) both in patients with HF and reduced left … Continue Reading about Empagliflozin and Renal Outcomes in Heart Failure
Value of real-world DOAC data on atrial fibrillation treatment
Following the approval of direct oral anticoagulants (DOACs) a number of real-world studies were initiated to look at their impact on atrial fibrillation (AF) patients seen in daily practice. Unlike randomized … Continue Reading about Value of real-world DOAC data on atrial fibrillation treatment